ericytes are vascular mural cells that are embedded in the basement membrane of brain capillaries 1, 2 . They extend their processes to the neighboring brain capillaries, pre-capillary arterioles and post-capillary venules. In the central nervous system (CNS), pericytes are positioned centrally within the neurovascular unit between brain capillary endothelial cells that form the bloodbrain barrier (BBB), astrocytes and neurons 2 . They have a key role in signaling within the neurovascular unit at the brain capillary level and regulate multiple neurovascular functions. This includes angiogenesis during CNS development 3 , BBB permeability in the developing and adult CNS [4] [5] [6] , clearance of toxic metabolites [7] [8] [9] , blood flow responses [10] [11] [12] [13] , inflammatory responses and stem cell activity 2 . Pericyte loss is found in both acute and chronic CNS disorders 14 . They die rapidly after ischemic stroke 11 and brain trauma 15 , and degenerate in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common genetic form of stroke 16 . Massive regional loss of pericytes has been shown in Alzheimer's disease 1, 14, 17, 18 , amyotrophic lateral sclerosis (ALS) . However, their role in the pathogenesis of these acute and chronic CNS disorders still remains debatable.
. They extend their processes to the neighboring brain capillaries, pre-capillary arterioles and post-capillary venules. In the central nervous system (CNS), pericytes are positioned centrally within the neurovascular unit between brain capillary endothelial cells that form the bloodbrain barrier (BBB), astrocytes and neurons 2 . They have a key role in signaling within the neurovascular unit at the brain capillary level and regulate multiple neurovascular functions. This includes angiogenesis during CNS development 3 , BBB permeability in the developing and adult CNS [4] [5] [6] , clearance of toxic metabolites [7] [8] [9] , blood flow responses [10] [11] [12] [13] , inflammatory responses and stem cell activity 2 . Pericyte loss is found in both acute and chronic CNS disorders 14 . They die rapidly after ischemic stroke 11 and brain trauma 15 , and degenerate in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common genetic form of stroke 16 . Massive regional loss of pericytes has been shown in Alzheimer's disease 1, 14, 17, 18 , amyotrophic lateral sclerosis (ALS) 19 , human immunodeficiency virus (HIV)-associated neurocognitive disorder 20 , Parkinson's disease and Huntington's disease, as reviewed recently 1, 14 . However, their role in the pathogenesis of these acute and chronic CNS disorders still remains debatable.
One of the key obstacles to better understanding the role of CNS pericytes is a lack of pericyte-specific models, including a pericytespecific Cre line and pericyte-specific ablation models. To overcome this difficulty, we generate an inducible pericyte-specific Cre line using a double-promoter approach with platelet-derived growth factor receptor-β (Pdgfrb) 21 and chondroitin sulfate proteoglycan 4 (Cspg4) 22 promoters. To ablate pericytes without affecting other brain cell types, we cross pericyte-specific Cre mice with iDTR mice carrying Cre-dependent human diphtheria toxin receptor (DTR) 23 . We then ablate pericytes with diphtheria toxin, and study the link between pericyte loss and neuron loss and/or degeneration.
Results
Generation of the pericyte-specific Cre line. The canonical markers of brain pericytes are typically shared with other brain cell types 2 . Therefore, to generate a pericyte-specific line we employed a double-promoter strategy, using both Pdgfrb (ref. 21 ) and Cspg4 (ref. 22 ) promoters. We reasoned that combining these two promoters that drive expression of Pdgfrb and Cspg4 genes, which are enriched in pericytes relative to other brain cell types [24] [25] [26] [27] ( Supplementary Fig. 1a-d) , will focus Cre recombinase expression to pericytes ( Supplementary Fig. 1e ). We made two constructs: one expressing flippase (Flp) recombinase under the control of the Pdgfrb promoter, and the other carrying a Frt-Stop-Frt-CreER cassette (Frt is the flippase recognition target and CreER is the recombinant protein between Cre recombinase and a mutated ligand binding domain of the estrogen receptor 28 ) under the control of the Cspg4 promoter (Fig. 1a, left ). Initially, we tested cell specificity of the two-promoter strategy in primary mouse brain endothelial cells, pericytes and vascular smooth cells (VSMCs). After co-transfection with Cspg4-FSF-CreER, Pdgfrb-Flp and a Credependent green fluorescent protein (GFP) reporter, the only cell type that allowed expression of both Flp and CreER, resulting in GFP expression, was pericytes ( Supplementary Fig. 1f,g ).
Next, we generated Pdgfrb-Flp;Cspg4-FSF-CreER mice by co-injecting both linearized constructs into C57BL/6 blastocysts Articles NATuRe NeuROSCIeNCe (Fig. 1a, left) . To characterize Cre expression, we crossed a line that stably carried Pdgfrb-Flp and Cspg4-FSF-CreER cassettes ( Supplementary Fig. 2a,b) with the Ai14 tdTomato reporter line 29 ( Fig. 1a, right) . Tamoxifen (TAM) treatment, led to tdTomato expression only in the mural cells on CD31
+ endothelial brain capillary profiles (≤6 µm in diameter) 4, 5 , but not on larger arteriolar vessels (Fig. 1b,c) or mural α-smooth muscle actin (SMA) + VSMCs of small arterioles 24 ( Fig. 1d,e) . tdTomato colocalized exclusively with CD13 + (Fig. 1f) or PDGFRβ + ( Supplementary Fig. 2c ) pericytes 4, 5 but not CD31 + endothelial cells (Fig. 1f) . Olig2 + oligodendrocytes ( Supplementary Fig. 2d ), GFAP + astrocytes ( Supplementary  Fig. 2e ,f), NeuN + neurons ( Supplementary Fig. 2g ), or ionized calcium binding adaptor molecule 1 (Iba1)-positive microglia ( Supplementary Fig. 2h ) did not express tdTomato. TAM treatment (2, 4 and 7 injections of 40 mg kg −1 daily) increased tdTomato expression dose-dependently in CD13
+ pericytes (Fig. 1g,h ), which indicated that we had generated an inducible pericyte-specific Cre line. See Methods for more details on the double-promoter strategy.
Pericyte ablation with diphtheria toxin. To ablate pericytes, we crossed pericyte-CreER mice with iDTR mice carrying Cre-dependent human DTR 23 , which leads to cell death after diphtheria toxin (DT) administration 23, 30 ( Fig. 2a) . TAM treatment (40 mg kg −1 daily for 7 consecutive days), and DT treatment (0.1 µg daily for 10 consecutive days beginning 2 weeks after TAM) or vehicle, were modified from studies in which DTR-expressing oligodendrocytes 23 and microglia 31 were ablated (Fig. 2b) . All analyses were performed at 0, 3, 6 and 9 d during DT treatment, and 3 and 15 d post-DT treatment (Fig. 2b) . TAM-induced DTR expression in brain capillaries of pericyte-CreER;iDTR mice, and subsequent DT treatment depleted brain capillary DTR, which was associated with a loss of PDGFRβ, a pericyte marker 4, 5, 32 , but not CD31, a brain endothelial marker 4, 5, 32 , as shown by immunoblotting (Fig. 2c,d ). As brain capillaries did not contain SMA + VSMCs 24 ( Fig. 2c ), these data suggested that DT kills PDGFRβ + pericytes. Tissue analysis confirmed progressive loss of tdTomato + CD13 + pericytes on cortical and hippocampal capillaries (≤6 µm in diameter) from 35% (6 d during DT) to 95% and 100% at 3 and 15 d post DT, respectively, compared to vehicle (Fig. 2e,f) . This led to approximately 20%, 40% and 60% loss of CD13 + pericytes 32 at 6 and 9 d during DT, and 3-15 days post DT, respectively (Fig. 2g) , and the accompanying loss of CD13 + pericyte coverage (Fig. 2h,i) . ) and at 7 versus 4 TAM injections (P = 8.5 × 10
−8
). Mean ± s.e.m., n = 5 mice per group. Significance was assessed by one-way ANOVA followed by Bonferroni post hoc test. Scale bars, 20 μm in panels c, d, g. Experiments illustrated in panels b-d, f and g were repeated independently with similar results in five mice.
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TUNEL staining further confirmed that DT kills tdTomato + CD13 + pericytes (Fig. 2j,k) . Consistent with lack of tdTomato expression in SMA + VSMCs (Fig. 1b-e) , DT did not ablate VSMCs in TAM-treated pericyteCreER;iDTR mice, as shown by no change in the thickness of the VSMC-covered arteriolar wall (Fig. 2l,m) , the number of VSMCs (Fig. 2n) , and/or the cerebral blood flow (CBF) response to adenosine, an endothelium-independent VSMC relaxant 13 ( Fig. 2o) , which suggests that VSMC function is intact. DT also did not ablate astrocytes, microglia or oligodendrocytes (Supple mentary Fig. 3a-d) .
Acute circulatory failure after pericyte ablation. To determine whether pericyte loss affects CBF, we used longitudinal dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) with gadolinium, which generates regional CBF values in mice comparable to values generated by 'gold standard' 14 C-iodoantipyrine autoradiography 8 . DSC MRI revealed CBF loss in the cortex and hippocampus of TAM-treated pericyte-CreER;iDTR mice beginning at day 9 of DT, followed by 50% CBF reductions at 3 and 15 d post DT (Fig. 3a,b) , which has been confirmed independently with an iron oxide contrast agent ( Supplementary Fig. 4a ).
The BBB unidirectional transfer constant, K trans , which maps to gadolinium generated by longitudinal dynamic contrast-enhanced (DCE) MRI 8 , indicated BBB breakdown in the cortex and hippocampus of TAM-treated pericyte-CreER;iDTR mice, beginning at day 6 of DT (corresponding to the first detectable (~20%) loss of pericytes) and advancing to a >60% increase in the K trans values compared to vehicle at both 3 and 15 d post DT (Fig. 3c,d) , which corresponds to a 60% loss of pericytes. Tissue analysis of perivascular immunoglobulin G (Fig. 3e ,f) and fibrinogen ( Supplementary Fig. 4b ,c) deposits confirmed BBB breakdown that was most pronounced in vessels that lacked pericyte coverage ( Supplementary Fig. 4d ).
Consistent with BBB breakdown, the length of the tight junction proteins zonula occludens and occludin, and the adherens junction protein VE-cadherin 1 on cortical and hippocampal capillaries of TAM-treated pericyte-CreER;iDTR mice was reduced by 50-60% at 3 d post DT ( Supplementary Fig. 4e-j) , which has been confirmed by immunoblotting of brain capillaries ( Supplementary  Fig. 4k,l) . Electron microscopy analysis did not show evidence of enhanced transcytosis ( Supplementary Fig. 4m,n) .
To explore possible mechanisms of circulatory failure we studied whether pericyte cell death leads to a 'rigor mortis' hypercontractile state of dying pericytes, as shown after stroke 11 . However, cell death and contractility measurements of DTR-expressing mouse pericytes indicated that pericytes do not contract when killed by toxin ( Supplementary Fig. 5a ,b and Supplementary videos 1-3). Leukocyte plugging and platelet accumulation (thrombosis of vessels) also did not contribute to blood flow obstructions ( Supplementary Fig. 5c ). But diffusion MRI revealed development of vasogenic edema, as shown by 15-18% and >20% increase in the tissue apparent diffusion coefficient (ADC) at day 9 during DT and day 15 post DT compared to vehicle, respectively (Supplementary Fig. 5d-f) . The edema was less pronounced than after ischemic stroke ( Supplementary Fig. 5g ), and was driven by an early BBB breakdown ( Fig. 3c-f and Supplementary Fig. 5h -i). Consistent with tissue swelling, we found reduced red blood cell flow, and a decrease in capillary diameter ( Supplementary Fig. 5j -l) and reduced CBF (Fig. 3a,b) , which led to tissue hypoxia ( Supplementary Fig. 5m ,n) and accumulation of neurotoxic glutamate in the cerebrospinal fluid (CSF) at levels comparable to those seen after ischemic stroke ( Supplementary Fig. 5o ).
In contrast to BBB breakdown ( Fig. 3c-f ), edema (Supplementary Fig. 5d-g ) and CBF reductions (Fig. 3a,b) after global pericyte loss, ablation of single pericytes decreases flow resistance and dilates capillaries but does not disrupt the BBB 33 and/or lead to edema, probably owing to compensatory influences from nonablated neighboring pericytes 2 . Although pericytes establish the blood-retinal barrier (BRB) 34, 35 , one study has suggested they are , respectively), whereas relative abundance of CD31 was unchanged (P = 0.49). Mean ± s.e.m., n = 3 mice per group. PDGFRβ, pericyte marker; CD31, endothelial marker. e-g, tdTomato, CD13 and DAPI staining in the cortex 3 d post DT or vehicle (e) and quantification of tdTomato
+ pericytes (f) and CD13 + DAPI + pericytes (g) in the cortex (Ctx) and hippocampus (Hipp) of TAM-treated pericyte-CreER;Ai14;iDTR mice at 0, 3, 6 and 9 d during DT, and 3 and 15 d post DT or vehicle. Mean ± s.e.m., n = 5 mice per group. In e, white in merged image indicates colocalization of tdTomato, CD13 and DAPI (white arrows) and is representative of staining repeated independently with similar results in five mice. Scale bar, 20 µm. Inset bar, 10 µm. In f, compared to vehicle-treated mice, DT-treated mice had significantly fewer tdTomato ). In g, compared to vehicle-treated mice, DT-treated mice had significantly fewer CD13 + DAPI + cells in Ctx at day 6 of treatment (P = 1 × 10
), day 9 of treatment (P = 3 × 10 ) and 15 d post treatment (P = 9 × 10
−13
). h,i, CD13
+ pericyte coverage of lectin + endothelial profiles in the Ctx 3 d post DT or vehicle (scale bar in h, 20 µm), and quantification of pericyte coverage on capillaries (<6 μm in diameter) in Ctx and Hipp (i) in TAM-treated pericyte-CreER;iDTR mice at 0, 3, 6 and 9 d during DT, and 3 and 15 d post DT or vehicle. Mean ± s.e.m., n = 5 mice per group. In i, compared to vehicle-treated mice, DT-treated mice had significantly less capillary pericyte coverage in Ctx at day 6 of treatment (P = 8 × 10 ), day 9 of treatment (P = 1.8 × 10 
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Pericytes in peripheral organs (for example, kidney, liver, heart) were only sparsely labeled in the present model (Supplementary Fig. 6a-d 24, 27 . For example, in the kidney, <5% of PDGFRβ + pericytes express NG2 (refs. 36,37 ). As the present model requires both genes to be expressed in the cell at the same time, it is not surprising that peripheral pericytes in the kidney have not been affected. In addition, we show that ablation of brain pericytes does not affect systemic physiological and biochemical parameters, the results of liver and kidney analyses ( Supplementary Fig. 6e-g ), or visual perception (acuity) (Supplementary Fig. 6h ).
Rapid neuron loss after pericyte ablation. Unexpectedly, we found rapid loss of neurons and behavioral deficits within days of pericyte ablation, as shown by 20-25% loss of NeuN + neurons and 35-40% loss of SMI312 + neuritic density in cortex and hippocampus ( Fig. 3g-i ) accompanied by poor performance on novel object location and fear conditioning tests, as shown 15 d post DT (Fig. 3j,k) . In the absence of DTR-expressing pericytes, control iDTR mice treated with TAM and DT, and pericyte-CreER;iDTR mice treated with TAM and vehicle, did not show circulatory ( Supplementary Fig. 7a-g ), neuronal ( Supplementary Fig. 7h -j) or behavioral ( Supplementary Fig. 7k ,l) changes.
Loss of pericyte-derived pleiotrophin-mediated neuroprotection. To address why pericyte ablation leads to rapid neuron loss, we next asked whether rapid pericyte loss deprives neurons of pericyte-derived neurotrophic support. We focused on pleiotrophin (PTN)-a pericyte-secreted growth factor that is expressed in the brain but not in peripheral organs 38 , and whose expression is enriched in pericytes compared to other brain cell types 5, 24, 39 -and/ or other growth factors secreted by pericytes 24 . Fig. 8a-c) . In addition, FISH confirmed Ptn mRNA expression in pericytes in isolated brain capillaries ( Supplementary  Fig. 8d ), and immunoblotting showed substantially higher PTN levels in brain pericytes than other CNS cell types, including brain endothelial cells, oligodendrocyte precursor cells, neurons, VSMCs and astrocytes ( Supplementary Fig. 8e ). Pericyte ablation resulted in 65% loss of Ptn + CD13 + pericytes, as shown by FISH (Fig. 4a,b ), >60% loss of PTN protein from brain capillaries, as shown by immunoblotting (Fig. 4c) , and approximately 65% loss of PTN from CSF at day 9 of DT treatment and day 15 post DT, as shown by sandwich immunoassay (Fig. 4d) .
At concentrations corresponding to physiological CSF PTN levels, both pericyte-conditioned media containing pericytesecreted PTN and mouse recombinant PTN protected mouse cortical and hippocampal neurons from cell death induced by withdrawal of neuronal growth medium, oxygen-glucose deprivation and glutamate toxicity ( Supplementary Fig. 8f-k) , which are models relevant to brain pathophysiology that develops after pericyte ablation in vivo ( Supplementary Fig. 5m-o) . In all models, the neuroprotective effects of pericyte-conditioned media were abolished by PTN-neutralizing antibody but not non-immune immunoglobulin G (IgG) ( Supplementary Fig. 8f-k) , consistent with the neuroprotective effects of PTN [40] [41] [42] . Moreover, restoration of PTN loss in pericyte-ablated mice through reinstatement of physiological CSF PTN levels by continuous intracerebroventricular (ICV) infusion of a recombinant mouse PTN from day 6 of DT treatment (when pericyte loss begins) until day 15 post DT completely prevented neuron loss and behavior deficits, in contrast to control infusion with artificial CSF (Fig. 4e-k) .
PTN infusion did not influence cerebrovascular dysfunction in pericyte-ablated mice, as indicated by no changes in pericyte loss, CBF loss or BBB breakdown ( Supplementary Fig. 9a -l), consistent with data that show that PTN knockout has no effect on brain vasculature in mice 40 . To determine whether PTN loss alone can trigger neuron loss in mice with intact pericyte coverage and normal circulatory function, we used short interfering RNA (siRNA) to geneti- ), day 9 of treatment (P = 2.6 × 10 (Fig. 4f-k) over the same period of time that was required for neuron loss to develop after pericyte ablation, and did not affect pericyte coverage ( Supplementary Fig. 9a -c) or cerebrovascular integrity ( Supplementary Fig. 9g -l). These data suggest that PTN loss is not sufficient to precipitate neuron loss in the absence of circulatory stress that also develops after pericyte loss ( Fig. 3a-i ). To confirm that circulatory stress is indeed needed to trigger neuron loss in mice with depleted PTN, we challenged siPtn-treated mice with ischemic stroke and excitotoxic lesions. Compared to control siRNA, Ptn silencing increased the injury volume and the number of fluoro-jade + degenerating neurons by 50-60% in both models (Fig. 4l-s) , consistent with the idea that PTN loss renders neurons vulnerable to circulatory stress.
Discussion
Our study reveals a rapid neurodegeneration cascade that links pericyte loss to neuron loss by two parallel pathways: (1) acute circulatory failure including BBB disruption, development of vasogenic edema and loss of blood flow; and (2) loss of PTN neuro trophic support (Fig. 4t) , which are both required to trigger rapid neuron loss.
In contrast to rapid loss of neurons in pericyte-ablated adult mice, congenital pericyte-deficient mice either do not develop neuron loss, as shown in a model with reduced bioavailability of endothelial platelet-derived growth factor-B (PDGF-BB) 5, 43 , or develop a late-appearing neuron loss occurring 6-8 months after pericyte loss, as shown in models of globally inherited PDGFRβ deficiency 4, 13 . However, PDGFRβ-deficiency in these mouse models is not pericyte-specific, and direct loss of PDGFRβ from neural cells 44, 45 might also have a role in late neuron loss reported in this model 4 . Fast loss of neurons in pericyte-ablated adult mice-that is, 20 times faster than in PDGFRβ-deficient mice-is probably related to the 60-80 times faster loss of pericytes which causes acute circulatory failure that has not been found in previous pericytedeficient models 4, 5, 43 . Whether compensatory responses during brain development can influence vascular and/or neuronal phenotypes in PDGFRβ-deficient mice, which is not the case in the present ablation model, remains unknown and should be addressed by future studies.
Our findings show that pericytes provide a major source of PTN for the brain compared to other CNS cell types. This is consistent with single-cell RNA sequencing (RNA-seq) work that demonstrated predominant expression of Ptn in pericytes compared to low expression in astrocytes, oligodendrocytes and endothelial cells 24 , and findings in Ptn-EGFP BAC mice (GENSAT project) that showed abundant Ptn expression in brain vascular profiles, consistent morphologically with pericytes, but not in other non-vascuar cells in the brain parenchyma 39 . In contrast to our findings and those of others 5, 24, 39 , another recent single-cell transcriptome study using wild-type mice suggested that other CNS cell types (for example, arterial endothelial cells) express high levels of Ptn
46
. However, single-cell transcriptome studies using endothelial-specific and pericyte-enriched mouse models suggest that fibroblast markers (for example, Igfbp2, Pdgfra, Lum, Dcn, Il33) 24 were associated with 'arterial endothelial cells' in this study 46 , which suggests a possible contamination of endothelial cells by perivascular fibroblast subtype FB1 (ref. 24 ). Previous work using endothelial-specific models 24 did not find Pdgfra expression in endothelial cells. Therefore, high Ptn expression that is associated with arterial endothelial cells 46 probably reflects contamination from either physically associated endothelial-fibroblast cell doublets, or fibroblast cell fragments. Compared to brain capillary pericytes, there are only a few FB1 fibroblasts in the CNS localized in penetrating arteries but not capillaries 24 . Thus, neuronal loss that we see in the hippocampus and cortex after pericyte ablation cannot be explained by pericyteinduced loss of PTN in FB1 fibroblasts. ). In b-d, data are shown as mean ± s.e.m., n = 3 mice per group. e-i, NeuN + neurons (red, e) and SMI312 + neurofilaments (green, e) in Ctx and Hipp of TAM-treated pericyte-CreER;iDTR mice receiving DT for 10 d and PTN or aCSF by ICV bilateral infusion (from day 6 during DT to 15 d post DT), and quantification of NeuN + neurons (f,g) and SMI312 + neuritic density (h,i) in Ctx and Hipp after PTN and aCSF infusion compared to 2 weeks post siPtn or siControl (scrambled siRNA) ICV treatment of TAM-treated pericyteCreER;iDTR mice receiving vehicle. Mean ± s.e.m., n = 5 mice per group. Scale bar in e, 20 µm. In f, compared to TAM + DT + aCSF-treated mice, TAM + DT + PTN-treated mice had significantly higher numbers of NeuN + neurons in Ctx (P = 1.7 × 10 −5
), whereas compared to TAM + siControl-treated mice, TAM + siPtn-treated mice showed no difference (P = 0.99). In g, compared to TAM + DT + aCSF-treated mice, TAM + DT + PTN-treated mice had significantly higher numbers of NeuN + neurons in Hipp (P = 3 × 10
), whereas compared to TAM + siControl-treated mice, TAM + siPtn-treated mice showed no difference (P = 0.99). In h, compared to TAM + DT + aCSF-treated mice, TAM + DT + PTN-treated mice had significantly higher SMI312 + neuritic density in Ctx (P = 9 × 10 −6
), whereas compared to TAM + siControl-treated mice, TAM + siPtn-treated mice showed no difference (P = 0.99). In i, compared to TAM + DT + aCSF-treated mice, TAM + DT + PTN-treated mice had significantly increased SMI312 + neuritic density in Hipp (P = 2.1 × 10
), whereas compared to TAM + siControl-treated mice, TAM + siPtn-treated mice showed no difference (P = 0.53). j,k, Novel object location (j) and fear conditioning (k) in TAM-treated pericyte-CreER;iDTR mice receiving DT for 10 d and PTN or aCSF ICV infusions at 15 d post DT or 2 weeks after siPtn or siControl ICV treatment of TAM-treated pericyte-CreER;iDTR mice. Mean ± s.e.m., n = 5 DT + aCSF, 7 DT + PTN, 7 siPtn and 6 siControl (j) or 5 siControl (k) mice per group. In j, compared to TAM + DT + aCSF-treated mice, TAM + DT + PTN-treated mice had significantly higher exploratory preference (P = 3.9 × 10 −5
), whereas compared to TAM + siControl-treated mice, TAM + siPtn-treated mice showed no difference (P = 0.99). In k, compared to TAM + DT + aCSF-treated mice, TAM + DT + PTN-treated mice had significantly higher performance on fear conditioning (P = 2.5 × 10 ) and increased number of Fluoro-Jade + neurons (o, P = 9.7E
−3
). In q and s, siPtn-treated mice compared to siControl-treated mice had larger lesion volume (q, P = 6.1 × 10
) and increased number of Fluoro-Jade + neurons (s, P = 7.8 × 10 
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A recent single-cell transcriptome study also showed that the cell type with the highest Ptn expression in the CNS is olfactory glial cells 46 . These cells are found exclusively in the olfactory bulb, not other CNS regions. Therefore, again it is highly unlikely that olfactory unsheathing cells contribute to neuronal injury and loss in the cortex and hippocampus after pericyte ablation in these regions, as we show here. Interestingly, a study using wild-type mice 46 suggested that there are three subtypes of brain pericytes that express Ptn at levels lower than those reported by a previous single-cell transcriptome study that used a pericyte-enriched mouse model, which indicated a single cell type of pericytes in brain 24 . An in-depth investigation into single-cell RNA-seq data from recent reports using endothelial-specific and/or pericyte-enriched mouse models 24, 47 , reveals that typical endothelial cell markers such as claudin 5 (Cldn5), Adgrf5 and Emcn are found associated with the suggested pericyte 1 and 2 subtypes 46 . Previous and recent reports 24, 47 have shown that claudin 5 is a classical endothelial-specific tight junction protein 1 . In addition, markers that are 
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NATuRe NeuROSCIeNCe suggested to be specific for the pericyte 2 subtype (for example, Cd82, Chst1, Apln) 46 are actually expressed by venous endothelial cells, as reported by a study using endothelial-specific models 24 . Thus, there is a possibility that the reported three pericyte subtypes 46 are actually endothelial-pericyte doublets or pericyte contaminants with different endothelial fragments, in which case it would be difficult to evaluate cell-specific gene expression in pericytes.
Finally, a study using an astrocyte-specific model 48 found high Ptn expression in astrocytes that we were not able to show in the present study by either FISH for Ptn mRNA and astrocyte marker GFAP (Supplementary Fig. 8b ) or by immunoblotting of cultured astrocytes ( Supplementary Fig. 8e ), similar to findings in a recent single-cell transcriptome study 24 and Ptn-EGFP BAC mice
39
. The discrepancy between these studies remains unclear, but it might be related to genetic differences between mouse strains, such as FVB 48 compared to C57BL/6 in the current and previous 24 ,39 studies, consistent with strain-specific gene expression in the adult mouse CNS 49 . Acute pericyte loss in the present ablation model mimics well the pathophysiological events seen after ischemic stroke, such as rapid BBB breakdown, vasogenic edema and loss of tight junctions. However, after stroke these events result primarily from an acute loss of blood flow, whereas in the present ablation model BBB breakdown after massive loss of pericytes occurs a little before loss of blood flow. The relevance of the present findings to the pathogenesis of chronic neurodegenerative disorders associated with massive regional loss of pericytes and BBB breakdown such as Alzheimer's disease 1, 14, 17, 18 , ALS 19 , HIV-associated neurocognitive disorder 20 , Parkinson's disease and Huntington's disease, is less clear and remains to be determined by future studies. These studies could use preclinical models of these neurological disorders with different degrees of pericyte ablation. Interestingly, recent findings in the living human brain have suggested that pericyte degeneration and BBB breakdown are early independent biomarkers of human cognitive dysfunction 50 . Nevertheless, whether pericytes die slowly or rapidly in different chronic neurological disorders mandates future studies.
In summary, the present study provides new insights into the pathophysiological mechanisms that link pericyte loss to rapid neuron loss and degeneration. The novel role of pericytes in regulation of PTN levels, the consequences for neuroprotection in different pathological scenarios, and how exactly PTN mediates neuroprotection at the molecular level are exciting research directions for future studies. Overall, the present findings may have implications for better understanding the pathogenesis and treatment of acute and chronic CNS disorders associated with pericyte loss and/or neurovascular dysfunction.
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Methods
Animals. Mice were housed in plastic cages on a 12 h light/dark cycle with access to water ad libitum and a standard laboratory diet. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Southern California, and followed National Institutes of Health guidelines. All animals were included in the study. Male and female animals of 2-3 months of age were used in the experiments. All animals were randomized for their genotype information. All experiments were carried out blind: the operators responsible for the experimental procedures and data analysis were blinded and unaware of group allocation throughout the experiments. All mice studied, including pericytespecific Cre mouse line, the Ai14 Cre reporter mice and iDTR mice (see subsections below), were on the same C57Bl/6 background.
Generation of the pericyte-specific Cre mouse line.
A double-promoter approach was used to achieve pericyte-specific expression of Cre recombinase (Fig. 1a) . More specifically, we generated two constructs: (1) 22, 52 , using a BAC construct carrying the whole mouse Cspg4 gene and a targeting construct (provided by A. Nishiyama at the University of Connecticut) following a standard bacterial recombineering protocol 53 . First, we tested expression of both constructs in cultured primary murine pericytes, brain endothelial cells and VSMCs, and showed that only pericytes co-transfected with Cspg4-FSF-CreER, Pdgfrb-Flp and a GFP reporter, but not endothelial cells or VSMCs, successfully expressed GFP ( Supplementary Fig. 1f,g ). The constructs linearized with restriction endonucleases and purified with CsCl gradient method were then co-injected into C57BL/6 blastocysts via pronuclear injection at the Transgenic/Knockout Rodent Core at the University of Southern California. Three litters of 25 pups were born, of which 5 were identified as carrying both Pdgfrb-Flp cassette and Cspg4-FSF-CreER cassette. One founder line (Pdgfrb-Flp; Cspg4-FSF-CreER) was established and verified by PCR and western blotting, showing Flp expression in brain microvessels ( Supplementary Fig. 2a,b) but not capillarydepleted brain. The Pdgfrb-Flp; Cspg4-FSF-CreER line was characterized further by crossing to Ai14 Cre reporter mice that harbor a loxP-flanked STOP cassette that prevents transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato; Jackson Laboratory, stock no. 007908) 29 . Administration of 40 mg kg
of tamoxifen intraperitoneally (i.p.) for 7 consecutive days 54 (Sigma no. T-5648) released the expression of tdTomato, specifically in pericytes and not in other brain cell types, including endothelial cells, smooth muscle cells, oligodendrocytes, neurons, astrocytes, and microglia (Fig. 1b-e and Supplementary Fig. 2c-h ).
Our initial reasoning for using a double-promoter strategy was based on: (1) data that showed that PDGFRβ is not expressed in oligodendrocyte precursor cells (OPCs), oligodendrocytes or endothelial cells, as shown by single-cell RNA-seq analysis 24 and/or immunoblotting of cultured pericytes, VSMCs, OPCs and endothelial cells (Supplementary Figs. 1a,b) ; and (2) the quantitative immunoblotting analysis of these cultured cells, which showed five-to sixfold greater expression of PDGRFβ and NG2 proteins in pericytes compared to VSMCs ( Supplementary Fig. 1a,b) , which has been confirmed by immunostaining for both proteins in pericytes and VSMCs on capillaries and arterial retinal vessels, respectively ( Supplementary Fig. 1c,d ) 27 . However, a recent single-cell RNA-seq study has shown that Pdgfrb mRNA levels are approximately 4-fold higher in pericytes than in VSMCs, but Cspg4 mRNA levels are approximately 1.2-fold higher than VSMC levels 24 . As the steady-state levels of proteins may or may not reflect rates of transcription, it is possible that a fortuitous combination of events led to successful pericyte-specific efficiency. However, a comparison of subunit stoichiometry and ribosome profiling versus RNA-seq reads has shown that RNA does not at all reflect subunit stoichiometry, whereas the translational landscape does reflect subunit stoichiometry 55 , which supports our initial idea that the level of proteins is important in our design. Nevertheless, the actual data ( Fig. 1 and Supplementary Fig. 2) show that the constructs and integration sites that were used led to high pericyte specificity and efficiency.
Diphtheria-toxin-dependent ablation of pericytes.
To generate the inducible pericyte ablation model, we crossed our pericyte-Cre or pericyte-Cre; Ai14 mice with iDTR mice (Jackson Laboratory no. 007900) for Cre-dependent expression of DTR (from simian Hbegf) 23 . Males and females from both lines were used for breeding and to maintain the colony. Two weeks after the end of tamoxifen treatment, 2-to 3-month-old pericyte-Cre;iDTR or pericyte-Cre;iDTR;Ai14 mice were administered i.p. 0.1 µg diphtheria toxin (DT, Sigma no. D0564) or vehicle per day for 10 consecutive days. Animals were studied at different time points during DT or vehicle treatment and 3 and 15 d post DT or vehicle injections. Male and female 2-month-old C3H/HeJ mice (Jackson Laboratory strain no. 000659), which are homozygous for retinal degeneration 1 mutation Pde6b rd1 , resulting in retinal degeneration and blindness by weaning age, were used as positive controls for the visual cliff test.
Capillary isolation and capillary-depleted brain collection, and primary cell cultures. Brain capillaries were isolated using dextran gradient centrifugation followed by sequential cell-strainer filtrations, and capillary-depleted brain was collected as described previously 56 . The isolated capillaries were collected in PBS and either lysed for immunoblot analysis, cytospun for fluorescent staining analysis, or processed to establish primary pericyte cell cultures, as described below. Capillary-depleted brain samples were lysed for immunoblot analysis.
Brain pericyte culture. Primary mouse brain pericytes were isolated for in vitro culturing, as described previously 7, 32 . Cultures were confirmed to be morphologically consistent with pericyte cultures and were PDGFRβ + , desmin Primary mouse pericytes that were isolated from iDTR mice were transduced with AAV-Cre (adeno-associated virus encoding Cre-recombinase) to render cells sensitive to DT. Pericytes that express human DTR were then treated with either vehicle, 1 × 10 -4 µg µl −1 DT or 75 mM potassium chloride (KCl) to measure pericyte contractility and cell death. Pericyte death was assessed using a LIVE/ DEAD Viability/Cytotoxicity Kit (Thermo Fisher, Catalog no. L3224). Pericyte contractility was assessed by measuring the change in the length of the pericyte along the long axis of the cell, and quantified at 20 min, the time point at which the KCl + control pericytes were fully contracted, and just prior to pericytes beginning to die in the DT-treated group. For the duration of the experiments, pericytes were incubated at 37 °C, 21% O 2 and 5% CO 2 in an incubation system for microscopy (KI4, Tokai Hit) and were imaged on a fluorescence microscope (BZ-9000, Keyence). Time-lapse videos were taken immediately upon addition of vehicle, DT or KCl at 3 frames min −1 for 45 min. Pericyte conditioned media for PTN assay and for treating neuronal cultures were collected from 70-80% confluent pericyte cultures 72 h after media change.
Brain endothelial culture. Primary mouse brain endothelial cells were isolated and cultured as described previously 57, 58 . Cultures were confirmed to be morphologically consistent with primary endothelial cultures with cobble stonelike shape and to be von Willebrand factor
-, NeuN -and Iba1 -, as we reported previously 32, 58 .
Brain VSMC culture. Primary mouse brain VSMCs were isolated and cultured as described previously 59, 60 . 59 .
Mouse oligodendrocyte culture. A2B5 + OPCs were isolated from cortices of P5 mouse pups by magnetic cell sorting (MACS, Miltenyi Biotec), as we described previously 8 .
Neuronal cultures. Neuronal cells were isolated from the cortex and hippocampus of embryonic day (E)14.5 mouse embryos as we described previously 61 . B27 withdrawal, oxygen and glucose deprivation, and glutamate challenges were preformed as described below:
(1) B27 withdrawal. Primary mouse cortical neurons were cultured for 10 d with B27 supplement followed by B27 withdrawal for 48 h. Pericyte conditioned media diluted to contain pericyte-secreted PTN levels at a concentration to match the mouse in vivo PTN CSF concentration (~ 3nM) with and without PTN neutralizing antibody (Anti-PTN, R&D systems, AF-252; 500 ng ml −1 ) or non-immune IgG (NI IgG, Santa Cruz, sc-2027, 500 ng ml −1 ), or mouse recombinant PTN (3.5 nM, R&D systems, 6580-PL) were added to media to assess neuronal survival. (2) Oxygen and glucose deprivation (OGD) and glutamate treatment. OGD and glutamate treatment were performed using 10-day-old neuronal cultures. For OGD, neuronal media were replaced with glucose-free DMEM (Invitrogen) supplemented with pericyte conditioned media with and without PTN neutralizing antibody, NI IgG, and mouse recombinant PTN as above, and then transferred to a humidified incubator chamber (Billups-Rothenberg) with 1% O 2 at 37 °C for 3 h . After 3 h, cells were removed from the chamber and processed for immunocytochemistry 24 h later. For glutamate treatment, 10 µm glutamate were added to neuronal media, as described previously 41 , and pericyte conditioned media, PTN neutralizing antibody, NI IgG, and PTN were added as above.
Astrocytes. Cortical astrocytes were isolated and cultured from P1 to P4 pups from B6 mice as described previously 62 .
Immunohistochemistry. Animals were anesthetized, perfused and brains were removed and postfixed as we described previously 8 . Kidney, liver, heart and skeletal muscle tissue were also collected, postfixed and cut 30 µm thick using a vibratome (Leica). Retinas were processed as described previously 63 . Brain sections were cut 30 µm thick and were blocked with 5% normal donkey serum (Vector Laboratories) and 0.1% Triton-X in 0.01 M PBS, and incubated with primary antibodies diluted in blocking solution overnight at 4 °C. All antibodies are listed in Supplementary  Table 1 . To visualize brain microvessels, sections were incubated with Dylight 488, 594 or 647-conjugated L. esculentum lectin as we have reported previously 4, 58 . After Articles NATuRe NeuROSCIeNCe incubation with primary antibodies, sections were washed in PBS and incubated with fluorophore-conjugated secondary antibodies (see Supplementary Table  1 ) and then mounted onto slides with DAPI (4′,6-diamidino-2-phenylindole) fluorescence mounting medium (Dako). Sections were imaged with a Zeiss LSM 510 confocal laser-scanning microscope, as we described previously 8 . Z-stack projections and pseudo-coloring were performed using ZEN software (Carl Zeiss Microimaging). Image post-analysis was performed using ImageJ software. See Supplementary Table 1 for antibody details and dilutions used.
In situ fluorescent TUNEL staining. Tissue was incubated for 30 min in 20 µg ml −1 proteinase K and the In Situ Cell Death Detection Kit (Roche) was used as per the manufacturer's instructions. Sections were mounted onto slides as described above. For quantification, TUNEL + cells that also demonstrated tdTomato + pericyte expression were quantified using the ImageJ Cell Counter analysis tool. In each animal, five randomly selected fields from the cortex were analyzed in three nonadjacent sections (~100 μm apart). Three animals per group were analyzed.
Quantification. For pericyte coverage and numbers, extravascular leakages, NeuN
+ neuronal nuclei counting, MAP2 + neuron counts, neurofilament (SMI-312) + , oligodendrocyte counts, microglial quantification, and GFAP + astrocyte counting, and aquaporin 4 coverage, for each animal, four to six randomly selected fields in the somatosensory cortex region and/or the CA1 region of the hippocampus were analyzed in three to four non-adjacent sections (~100 μm apart), and averaged per mouse.
Pericyte coverage and numbers. For pericyte coverage and cell numbers, 10 μm maximum projection z-stacks (area 640 x 480 μm) were reconstructed, and the areas occupied by CD13 + (pericyte) and lectin + (endothelium) fluorescent signals or CD13
+ perivascular cell bodies that colocalized with DAPI + nuclei on the abluminal side of lectin + endothelium on vessels <6 µm were analyzed using ImageJ as we described previously 64 . Five animals per group were analyzed.
Smooth muscle cell wall thickness and number analysis.
For analysis of the VSMCcovered arteriolar vessel wall thickness, we studied penetrating arterioles (>25 µm in diameter) from cortical layer 1 in the somatosensory cortex region. SMA + segments (200 µm) were selected randomly for diameter measurements from maximum intensity projections of 30 µm optical stacks, as we reported previously 64 .
NeuN
+ neuronal nuclei counting. NeuN + neurons were quantified using the ImageJ Cell Counter analysis tool. Five animals per group were analyzed.
MAP2
+ neuron counts. For quantification of primary cortical and hippocampal cultured neuron numbers, four fields per coverslip from three coverslips were chosen randomly using a ×20 objective on a BZ-900 fluorescent microscope. The total number of MAP2 + DAPI + neurons was divided by the total number of DAPI + cells measured using ImageJ Cell Counter plugin. Data are expressed as the percentage of (MAP2 + DAPI + neurons/DAPI + cells) × 100, as reported previously 65, 66 . Neurofilament (SMI-312)-positive axons. As we described previously 4, 8 , 10 µm maximum projection z-stacks were reconstructed, and SMI-312 + signal was subjected to threshold processing and analysis using ImageJ. Five animals per group were analyzed.
Microglial quantification. The number of Iba1
+ microglia that also demonstrated DAPI + nuclear staining was quantified using the ImageJ Cell Counter analysis tool. Three animals per group were analyzed.
GFAP
+ astrocyte counting. The number of GFAP + astrocytes that also demonstrated DAPI + nuclear staining were quantified by using the ImageJ Cell Counter analysis tool. Three animals per group were analyzed.
Aquaporin 4 coverage.
Ten micrometer maximum projection z-stacks (area 640 × 480 µm) were reconstructed and aquaporin 4 expression around microvessels was quantified by calculating the area occupied by aquaporin 4 versus that occupied by lectin using ImageJ. Three animals per group were analyzed.
Oligodendrocyte counts. Ten micrometer maximum projection z-stacks were reconstructed, and the number of Olig2 + oligodendrocytes per mm 2 was determined using the ImageJ Software Cell Counter plugin analysis tool. Three animals per group were analyzed.
Immunofluorescent ZO-1 and occludin tight junction and VE-cadherin adherens junction analysis. The length of ZO-1, occludin and VE-cadherin
+ signals on lectin + capillary profiles in the cortex and the hippocampus was determined as we have reported previously 32 . The length of ZO1, occludin and VE-cadherin + tight and adherens junction proteins was normalized to the total area of lectin + microvessels using the ImageJ area measurement tool. Five animals per group were analyzed. Extravascular leakages. Perivascular blood-derived fibrin(ogen) and IgG deposits indicating BBB breakdown were measured as we described previously 4, 7, 32, 67 . For quantification of extravascular fibrin(ogen) (both fibrin and fibrinogen) deposits, an antibody that detects both fibrinogen and fibrinogen-derived fibrin polymers was used. Ten micrometer maximum projection z-stacks were reconstructed, and the fibrin(ogen) + perivascular signal on the abluminal side of lectin + endothelial profiles on microvessels <6 µm in diameter was analyzed using ImageJ 4, 64 . Five animals per group were analyzed. Western blots. Capillaries and capillary-depleted brains were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS, 1.0% NP-40, 0.5% sodium deoxycholate and Roche Protease Inhibitor Cocktail), subjected to SDS-PAGE (SDS-polyacrylamide gel electrophoresis) gel electrophoresis and transferred to a nitrocellulose membrane. Membranes were blocked with 5% milk, incubated with primary antibody, and then incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody. Membranes were then treated with Immobilon Western ECL detection buffers (Millipore), exposed to CLXPosure film (Thermo Scientific) and developed in a X-OMAT 3000 RA film processor (Kodak). Primary antibodies that were used for western blotting were rabbit monoclonal anti-mouse PDGFRβ (Cell Signaling, 3169S, 1:1,000), goat polyclonal anti-mouse CD31 (R&D Systems, AF3628, 1:1,000), mouse monoclonal anti-human DTR (BioAcademia, 71-501, 1:1,000), rabbit monoclonal anti-mouse VE-Cadherin (Abcam, ab205336, 1:1000), rabbit anti-ZO-1 antibody (Invitrogen, 40-2200, 1:1,000), mouse anti-occludin antibody (BD Biosciences, 611091, 1:500), rabbit anti-claudin 5 (Abcam, ab15106, 1:1,000), rabbit anti-PTN (Sino Biological, 51000-T40, 1:1,000), rabbit polyclonal Flp recombinase antibodies (OriGene, TA160030, 1:500), rabbit anti-GAPDH (Cell Signaling Technology, 5174S, 1:1,000), rabbit polyclonal anti-mouse β-actin (Cell Signaling, 4970S, 1:1,000), HRPconjugated horse anti-mouse secondary antibody (Cell Signaling, 7076S, 1:5,000) and HRP-conjugated donkey anti-rabbit secondary antibody (Invitrogen, A16023, 1:5,000).
Laser Doppler flowmetry CBF measurement. CBF response to 400 μm adenosine applied through an open cranial window was measured using laser Doppler flowmetry (LDF) in mice under 1% isoflurane anesthetic, as described 13, 68, 69 . The percentage increase in CBF due to adenosine application was obtained by subtracting the baseline CBF from the maximum value reached within 5 min of drug application, divided by the basal CBF value.
Magnetic resonance imaging. All magnetic resonance imaging (MRI) scans were performed using our MR Solutions 7T PET-MR system (bore size ~24 mm, up to 600 mT.m −1 maximum gradient (MR Solutions) and a 20 mm internal diameter quadrature bird cage mouse head coil.
Mice were anesthetized by 1-1.2% isoflurane in air. Respiration rate (72.0 ± 5.0 breaths per min) and body temperature (36.5 ± 0.5 °C) were monitored during the experiments, as we described previously 8 . The sequences were collected in the following order: T2-weighted imaging (2D-fast spin echo (FSE), TR/TE (time repetition/time echo) 4,000/26 ms, 32 slices, slice thickness 300 μm, in-plane resolution 100 × 70 μm 2 ) to obtain structural images; diffusion weighted echo-planar imaging (EPI, TR/TE 5,000/32, 14 slices, 1 b-value, 7 directions, slice thickness 300 μm, in-plane resolution 200 × 300 μm²) to assess brain edema; DCE protocol for the capillary permeability assessment; and finally, DSC imaging for regional cerebral blood flow. Total imaging time was approximately 40 min per mouse.
The DCE MRI imaging protocol was performed within the dorsal hippocampus region, and included measurement of pre-contrast T1 values using a variable flip angle (VFA) fast low angle shot (FLASH) sequence (FA (flip angle) = 5, 10, 15, 30 and 45°, TE = 3 ms, slice thickness 1 mm, in-plane resolution 60 × 120 μm 2 ), followed by a dynamic series of 180 T1-weighted images with identical geometry and a temporal resolution of 5.1 s (FLASH, TR/TE = 20/3 ms, flip angle 15°, slice thickness 1 mm, in-plane resolution 60 × 120 μm 2 ). Using a power injector, a bolus dose (140 μl) of 0.5 mmol kg −1 Gd-DTPA (gadoliniumdiethylenetriamine pentaacetic acid (Gd-DPTA), Magnevist, diluted in saline 1:4) was injected into the tail vein at a rate of 600 μl min . DCE images were collected during the 10 min following the injection. The DSC MRI imaging was performed on the exact same geometry. A dynamic series of 80 T2*-weighted images was used, with a temporal resolution of 1.4 s (FLASH, TR/TE = 18/3 ms, slice thickness 1 mm, flip angle 15°, in-plane resolution 120 × 230 μm 2 ). A second bolus dose of either (140 μl) of Gd-DTPA (1:1 dilution) or Ferimoxytol (Ferahene, 1:2 dilution) was injected into the tail vein at a rate of 1,000 μl min −1 . DSC images were collected during the 85 s following the injection.
MRI post-processing analysis. Capillary permeability assessment. T1 mapping. T1 relaxation times were estimated using the VFA method, prior to Gd-DTPA injection, with a series of FLASH images with varying FA and constant TR and TE using the standard saturation recovery equation:
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where SI is the signal intensity and where θ is the FA, E 1 = e −TR/T1 and E 2 = e −TE/T2* . Here, we assume that TE < T2*. Nonlinear least-squares was used to fit MRI data to the equation above.
K trans mapping. Post-processing of the collected DCE MRI data was performed using in-house DCE processing software (Rocketship) implemented in MATLAB 70 . The unidirectional capillary transfer constant, K trans , to intravenously injected gadolinium-based contrast agent was determined in both primary somatosensory cortex and hippocampus in mice using a modified method, as we reported in humans 71 with the post-processing Patlak analysis 8, 70, 72 . We determined the arterial input function (AIF) in each mouse from the common carotid artery, as reported previously 8, 71 .
Cerebral blood flow assessment. Following collection of the DSC MRI data, quantitative post-processing analysis was optimized as reported previously 8, 73 .
Brain edema assessment. Diffusion tensor imaging (DTI) EPI parametric maps were generated using DSI Studio (6 March 2018 build; http://dsi-studio.labsolver. org) as described previously 74 . The diffusion-weighted imaging data were pre-processed with motion, ghosting and eddy current corrections. After the co-registration of all individual images, data means were extracted for ADC (apparent diffusion coefficient; ×10 -3 mm 2 s -1) through DSI studio using the following equation:
where S 0 is the signal intensity without diffusion weighting, S is the signal with the diffusion gradient and b is the b-value. Regions of interest (ROIs) for primary somatosensory cortex and dorsal hippocampus were assigned manually by an investigator blinded to groups. To examine distinct changes, regional ROIs were drawn on ADC maps using boundaries defined by the Allen brain atlas (http://mouse.brain-map.org).
Behavioral tests. Novel object location.
The novel object location test was performed as reported previously 4, 7 . Four time points were analyzed in TAMtreated pericyte-CreER;iDTR mice: before DT (n = 7) or vehicle (n = 8) treatment, 6 d during DT (n = 9) or vehicle (n = 6) treatment, 3 d post DT (n = 7) or vehicle (n = 11) treatment, and 15 d post DT (n = 7) or vehicle (n = 14) treatment. PericyteCreER;iDTR mice were also evaluated at 15 d post DT treatment with PTN (n = 5) or artificial CSF (aCSF) (n = 7) ICV infusion, or 2 weeks after siPtn (n = 6) or siControl (n = 7) injections.
Contextual fear conditioning. The long-term memory formation paradigm in contextual fear conditioning was adapted from a protocol described previously 75 . During training, mice were placed in the conditioning chamber for 5 min and received 4 footshocks (0.25 mA, 1 s) at 1 min intervals starting 2 min after placing the mouse in the chamber. Contextual long-term memory was tested in the same chamber the next day without footshock applied. The experiment was performed in TAM-treated pericyte-CreER;iDTR mice 3 d post DT (n = 10) or vehicle (n = 10) treatment, 15 d post DT (n = 6) or vehicle (n = 9) treatment, 15 d post DT treatment with PTN (n = 5) or aCSF (n = 7) ICV infusion, or 2 weeks after siPtn (n = 5) or control siRNA (n = 7) injections.
Visual cliff test. The visual cliff test was performed as described previously 76, 77 with modifications. A transparent Plexiglas square arena (30 × 30 cm) was divided into two equal parts by aligning the middle of the arena with the edge of the table. The side on the tabletop was considered a 'shallow' side and the side positioned over the floor area (50 cm high) was considered a 'deep' side. A checkered paper floor (black and white 3 cm square pattern) was placed below the arenas: immediately below the Plexiglas surface on the shallow side, and on the floor on the deep side, creating an illusion of a cliff. The animals' behavior was recorded using Noldus Ethovision software with a camera placed above the arena. Each animal was placed on the shallow side and the total time spent exploring each side of the arena was recorded within a 5 min trial. The percentage time spent in the shallow side was analyzed.
In vivo two-photon laser scanning microscopy of red blood cell velocity and capillary diameter. Animals were initially anesthetized with 100 mg kg −1 of ketamine and 10 mg kg −1 of xylazine and were placed on a heating pad (37 °C). A 5 mm diameter cranial window was implanted over the somatosensory cortex as described previously 78 . Animals were allowed to rest for 3 h before imaging. Red blood cell (RBC) velocity through individual capillaries in the top 200 μm (layers I-II) of somatosensory cortex in mice under 0.5% isoflurane was determined using vessel linescans (113 lines s −1 , 120 nm pixel
) of RBC passage as detailed previously 13, 78 under resting conditions after retro-orbital injection with 70 kDa Texas Red (TxRed)-labeled dextran. Capillary segments were chosen randomly for diameter cross-section measurement using ImageJ from high resolution (120 nm pixel
) average intensity projections of 60 μm optical substacks through the same tissue volume as the velocity measurements. Cross-sections were analyzed for diameter in Igor Pro (WaveMetrics). Two measurements per vessel segment were averaged per vessel.
Hypoxia. For determination of hypoxic tissue, mice were injected i.p. with 60 mg kg −1 hypoxyprobe-1 pimonidazole (Hypoxyprobe-1 Plus Kit) as described previously 4, 8 .
Fluorescence in situ hybridization. RNA FISH was performed using the RNAscope technology (Advanced Cell Diagnostics). Tissue sample preparation and pretreatment were performed on both fresh frozen isolated microvessels cytospun onto glass slides and fixed brains cut into 20 μm coronal sections mounted onto SuperFrost Plus glass slides following the manufacturer's protocols (ACD documents 320513, 320535). After dehydration and pretreatment, slides were subjected to RNAscope Multiplex Fluorescent Assay (ACD document 320293). RNAscope probes for mouse Ptn, positive control and negative control were hybridized for 2 h at 40 °C in the HybEZ Oven and the remainder of the assay protocol was implemented. Subsequently, the slides were subjected to immunohistochemistry (see the Immunohistochemistry section). The fluorescent signal emanating from RNA probes and antibodies was visualized and captured using a Nikon A1R MP+ confocal/multiphoton microscope (Nikon). All FISH images presented are projections of ~6 μm z-stacks (0.3 μm intervals) obtained from cerebral cortex, and a smoothing algorithm was applied during image postprocessing (Nikon NIS-Elements Software).
Cerebrospinal fluid extraction and glutamate measurements. CSF was extracted as described previously 71, 79 . Glutamate was measured using the Glutamate Assay Kit (Sigma, MAK004) following the manufacturer's instructions.
PTN assay. PTN levels in mouse CSF and pericyte conditioned medium were measured by a sandwich immunoassay using the Meso Scale Discovery (MSD) platform. First, standard-bind 96-well plates (MSD, L15XA-3) were coated with a capture antibody (Sino Biological, 51000-T40) as per the manufacturer's instructions. After sample incubation, the plate was washed and then incubated for 1 h with human PTN biotinylated antibody, which cross-reacts with mouse PTN (R&D systems BAF252), and 1 μg ml −1 of Sulfo-tag labeled streptavidin (MSD). The plate was read immediately on the MSD SECTOR Imager 6000. The PTN concentrations in samples were calculated based on a recombinant mouse PTN (R&D systems, 6580-PL) standard curve.
Intracerebral osmotic pump implantation and infusion. To infuse mouse PTN into the brain, we used an MRI-compatible intracerebral infusion system that consists of a modified intracerebral 3 mm fused silica cannula with plastic hub (Alzet Brain Infusion Kit 3, DURECT; custom modified by Plastics One, product no. 3280PM-PK-SPC), which is connected to a small capsule-shaped osmotic pump (200 µl capacity; 3.0 cm length × 0.7 cm diameter; Alzet model 2004, DURECT) with Peek micro medical tubing (DURECT, product no. 0002612) that continuously infused PTN at 0.11 μl h −1 for up to 4 weeks. After filling up each pump and connected tubing with mouse recombinant PTN (R&D systems, 6580-PL; 15 µg ml −1 ) dissolved in aCSF or aCSF only, the osmotic pumps were surgically implanted subcutaneously in the flanks of sedated mice and secured with skin sutures on day 6 during DT injections. The intracerebral cannula was stereotaxically implanted bilaterally in both lateral ventricles at the location 0.3 mm caudal to the Bregma, 1.3 mm lateral of midline and 3 mm below the surface of the brain, and the hub was anchored to the cranial surface with cyanoacrylate adhesive. Surgical wounds were closed with cyanoacrylate adhesive and sutures over the hub. Mice were observed under radiant and blanket warmers until they had recovered from sedation and were monitored for ill effects. On a technical note, the PTN CSF measurements after infusion with aCSF and PTN (15 μg ml −1 ) indicated mean + s.e.m. PTN CSF levels of 0.93 + 0.04 nM (n = 3) and 3.19 + 0.39 nM (n = 4), respectively. This confirmed that aCSF-infused mice had levels comparable to those found in TAM-treated CreER;iDTR mice after pericyte ablation, whereas PTN-infused mice showed levels comparable to those found in control TAMtreated CreER;iDTR treated with vehicle (see Fig. 4d ). Of note, mouse CSF production is estimated to be 18 μl h −1 , or approximately165 times faster than the ICV infusion rate used here (that is, 0.11 μl h −1 ), which suggests that ICV infusion has minimal dilution effect. These results show that PTN infusion was able to increase PTN CSF levels and delivery of PTN to CNS after pericyte ablation to levels comparable to those found in control mice. siRNA gene silencing. To knock down Ptn in pericyte-Cre mice, we used Ptnspecific chemically modified, 21-mer, double-stranded Ambion In Vivo siRNA (Thermo Fisher), following our previously described approach 8 . As Ptn in mice is only expressed in the brain and not in peripheral tissues, as shown by the mouse genome project 38 , and is enriched in pericytes, as we ( Fig. 4a-c ; Supplementary  Fig 8d,e) and others 5, 24, 39 show, to short term silence Ptn we administered centrally siPtn or scrambled control siRNA by bilateral ICV injection.
Transient middle cerebral artery occlusion. Transient middle cerebral artery occlusion (MCAo) was performed as described previously, with modifications 80 .
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For stroke studies 2 weeks after siPtn or control siRNA ICV injections we used 30 min MCAo and 24 h reperfusion (Fig. 4l,m) ; for leucocyte and platelet control immunostaining we used 3 h MCAo and 24 h reperfusion ( Supplementary Fig. 5c ); for edema (ADC) values after stroke we used 1 h MCAo and 15 d reperfusion ( Supplementary Fig. 5g ). Infarction volume was determined as described previously 80 . Fluoro-Jade B staining (EMD Millipore, AG310) was performed as per the manufacturer's instructions.
NMDA treatment. Animals received NMDA injections in the right striatum (0.5 mm anterior, 2.0 mm lateral, 3.5 mm ventral) at a concentration of 20 nmol in 0.3 µl PBS, as described previously 81 , 2weeks after siPtn or control siRNA. Two days later the animals were euthanized and tissue was processed as described above.
Electron microscopy. Anesthetized vehicle and DT-treated animals were injected retro-orbitally with HRP type II (HRP ii; MW = 44 kDa) at a dosage of 10 mg per 20g of body weight (Sigma, P8250) and were euthanized 2 h later. Animals were perfused and brains were removed and cut as described previously 8 . HRPdiaminobenzidine (DAB) cytochemistry was performed on brain sections as per the manufacturer's instructions (Sigma, D3939). Sections were then processed as described previously 8 . Parts of the cortex were dissected carefully and placed on Epon blocks under a stereoscope. Blocks were coded, and all subsequent procedures were performed blind to genotypes. Sections (70 nm thick) were obtained on copper mesh grids using a Reichert ultramicrotome with a diamond knife (Diatome) and ultrastructural analysis was performed using a JEOL JEM-2100 transmission electron microscope as described previously 8 .
Analysis of systemic parameters. Heart rates were monitored by electrocardiography. For the respiration rate, an MRI pressure pad/respiration transducer was used (TSD110, Biopac Systems), with the anesthetized animal placed on top of the pad to record respiration. The pH, glucose levels and blood gases were determined from a small sample (~90 µl) of arterial blood, collected from the cannulated right femoral artery, using the i-STAT CG8+ panel (03P88-25, Abbott). For analysis of liver and kidney function, approximately 500 µl of serum was collected from the heart and sent to Idexx Reference Laboratories for screening (test codes 60405 and 60406, respectively).
Quantification and statistical analysis. Sample sizes were calculated using nQUERY, assuming a two-sided alpha-level of 0.05, 80% power and homogeneous variances for the 2 samples to be compared, with the means and common s.d. for different parameters predicted from published data and our previous studies 4, 7, 8, 13, 32 . Data are presented as mean ± s.d. or mean ± s.e.m. as indicated in the figure legends. For parametric comparison between two groups, an F test was conducted to determine the similarity in the variances between the groups, and statistical significance was analyzed using the Student's t-test. For multiple comparisons, Bartlett's test for equal variances was used to determine the variances between the multiple groups and one-way analysis of variance (ANOVA) followed by Bonferroni's post hoc test was used to test statistical significance, using GraphPad Prism software. Data were tested for normality using the Shapiro-Wilk test. A P value of less than 0.05 was considered statistically significant. Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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cell types including endothelial cells, smooth muscle cells, oligodendrocytes, neurons, astrocytes, and microglia (Fig. 1b-e and Fig. S2c-h ).
To generate inducible pericyte ablation model, we crossed our Pericyte-Cre or Pericyte-Cre; Ai14 mice with iDTR mice (Jackson Laboratory #: 007900) for Cre-dependent expression of diphtheria toxin receptor (DTR; from simian Hbegf). Males and females from both lines were used for breeding and to maintain the colony.
2-month old male and female C3H/HeJ mice (Jackson Laboratory strain # 000659), which are homozygous for retinal degeneration 1 mutation Pde6brd1, resulting in retinal degeneration and blindness by weaning age, were used as positive controls for the visual cliff test.
Wild animals
This study did not involve wild animals.
Field-collected samples
This study did not involve samples collected from the field.
Ethics oversight
All procedures were approved by the Institutional Animal Care and Use Committee at the University of Southern California with National Institutes of Health guidelines
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Magnetic resonance imaging Experimental design
Design type
All Pericyte-Cre; iDTR; Ai14 mice were scanned either cross-sectionnaly or longitudinally with our MR Solutions 7T PET-MR system (MR Solutions Ltd., Guildford, UK), bore size ~24-mm, up to 600 mT.m-1 maximum gradient and a 20-mm internal diameter quadrature bird cage mouse head coil.
Design specifications
Total imaging time was approximately 40 min per mouse. Mice were scanned cross-sectionnaly or longitudinally at different time points during DT or vehicle treatment and 3 and 15 days post-DT or vehicle injections.
Behavioral performance measures Mice were anesthetized by 1-1.2% isoflurane/air. Respiration rate (72.0 ± 5.0 breaths per minute) and body temperature (36.5 ± 0.5°C) are monitored during the experiments using an abdominal pressure-sensitive probe and a rectal temperature probe. The isoflurane dose and heated air flow was adjusted continuously to ensure stable and reproducible depth of anesthesia. ImageJ's Time Series Analyzer V3 plugin was used in real time to ensure good Gd or iron oxide bolus intravenous injection for both DCE and DSC scans.
Acquisition Imaging type(s)
Dynamic contrast-enhanced (DCE), dynamic susceptibility-contrast (DSC) and diffusion weighted imaging (DWI)
Field strength
7T
Sequence & imaging parameters
The sequences were collected in the following order: T2-weighted (2D-fast spin echo (FSE), TR/TE 4,000/26 ms, 32 slices, slice thickness 300 μm, in-plane resolution 100x70 μm2) to obtain structural images; diffusion weighted echoplanar imaging (EPI, TR/TE 5,000/32, 14 slices, 1 b-value, 7 directions, slice thickness 300 μm, in-plane resolution 200x300 μm²) to assess brain edema; dynamic contrast-enhanced (DCE) protocol for the capillary permeability assessment; and finally, dynamic susceptibility-contrast (DSC) imaging for regional cerebral blood flow. Total imaging time was approximately 40 min per mouse. The DCE-MRI imaging protocol was performed within the dorsal hippocampus territory, and included measurement of pre-contrast T1-values using a variable flip angle (VFA) fast low angle shot (FLASH) sequence (FA = 5, 10, 15, 30 and 45°, TE = 3 ms, slice thickness 1 mm, in-plane resolution 60x120 μm2), followed by a dynamic series of 180 T1-weighted images with identical geometry and a temporal resolution of 5.1 s (FLASH, TR/TE = 20/3 ms, flip angle 15°, slice thickness 1 mm, in-plane resolution 60x120 μm2). Using a power injector, a bolus dose (140 μL) of 0.5 mmol/kg Gd-DTPA (Gadolinium-diethylenetriamine pentaacetic acid, Magnevist®, diluted in saline 1:4) was injected via the tail vein at a rate of 600 μL/min. DCE images were collected over 10 min after the injection. The DSC-MRI imaging was performed on the exact same geometry. A dynamic series of 80 T2*-weighted images is used, with a temporal resolution of 1.4 s (FLASH, TR/TE = 18/3 ms, slice thickness 1 mm, flip angle 15°, in-plane resolution 120x230 μm2). A second bolus dose of either (140 μL) of Gd-DTPA (1:1 dilution) or Ferimoxytol (Ferahene®, 1:2 dilution) was injected via the tail vein at a rate of 1000 μL/min. DSC images were collected over 85 s after the injection.
Area of acquisition DCE and DSC scans: One coronal slice (thickness 1-mm) was selected within the dorsal hippocampus territory and the prefrontal cortex to guarantee having the hippocampus and primary somatosensory cortex as well as common carotid arteries for arterial input functions. DWI scans: The whole brain was scan coronally.
Diffusion MRI Used Not used
Parameters Diffusion weighted echo-planar imaging (EPI, TR/TE 5,000/32, 14 slices, 1 b-value, 7 directions, slice thickness 300 μm, in-plane resolution 200x300 μm²) to assess brain edema via apparent diffusion coefficient (ADC) parametric maps.
